Efgartigimod as Rescue Medication in a Patient with Therapy-Refractory Myasthenic Crisis.

IF 0.9 Q4 CLINICAL NEUROLOGY Case Reports in Neurological Medicine Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI:10.1155/2024/9455237
Omar Alhaj Omar, Norma J Diel, Stefan T Gerner, Anna Mück, Hagen B Huttner, Heidrun H Krämer-Best
{"title":"Efgartigimod as Rescue Medication in a Patient with Therapy-Refractory Myasthenic Crisis.","authors":"Omar Alhaj Omar, Norma J Diel, Stefan T Gerner, Anna Mück, Hagen B Huttner, Heidrun H Krämer-Best","doi":"10.1155/2024/9455237","DOIUrl":null,"url":null,"abstract":"<p><p>Myasthenic crises (MC) are potentially life-threatening acute exacerbations of myasthenia gravis (MG) characterized by profound muscle weakness, bulbar symptoms, and potential for respiratory failure. Intravenous immunoglobulins (IVIG) and plasma exchange (PLEX) are conventional treatments for myasthenic exacerbations. Recently, new therapeutic options for generalized acetylcholine-receptor antibody positive (AchR+) MG were approved as an add-on therapy. They mainly consist of complement C5 inhibitors such as eculizumab and ravulizumab and neonatal Fc receptor antagonists such as efgartigimod with the approval of more options pending, e.g., zilucoplan and rozanolixizumab. More therapeutic options are in the pipeline. Although the data show a quick and reliable treatment response, these medications have not been studied for the therapy of myasthenic crisis. We present the case of a 57-year-old male with his first episode of generalized myasthenia gravis (MG) and positive acetylcholine-receptor antibodies (AchR+) who was transferred to our neurological intensive care unit with worsening generalized weakness, dysphagia, and respiratory distress. The crisis was triggered by pneumonia due to dysphagia. He was diagnosed with myasthenic crisis and treated with intravenous pyridostigmine, plasmapheresis (PLEX), and continued prednisone. Initial improvement was followed by deterioration, requiring readmission and additional PLEX. After a further decline, efgartigimod was administered, leading to significant improvement within 48 hours, as evidenced by reduced MG-ADL and QMG scores. The patient continued to improve and was stable enough for transfer to a rehabilitation facility. This case illustrates the potential of efgartigimod as a novel treatment for refractory myasthenic crises.</p>","PeriodicalId":9615,"journal":{"name":"Case Reports in Neurological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11211016/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Neurological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/9455237","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Myasthenic crises (MC) are potentially life-threatening acute exacerbations of myasthenia gravis (MG) characterized by profound muscle weakness, bulbar symptoms, and potential for respiratory failure. Intravenous immunoglobulins (IVIG) and plasma exchange (PLEX) are conventional treatments for myasthenic exacerbations. Recently, new therapeutic options for generalized acetylcholine-receptor antibody positive (AchR+) MG were approved as an add-on therapy. They mainly consist of complement C5 inhibitors such as eculizumab and ravulizumab and neonatal Fc receptor antagonists such as efgartigimod with the approval of more options pending, e.g., zilucoplan and rozanolixizumab. More therapeutic options are in the pipeline. Although the data show a quick and reliable treatment response, these medications have not been studied for the therapy of myasthenic crisis. We present the case of a 57-year-old male with his first episode of generalized myasthenia gravis (MG) and positive acetylcholine-receptor antibodies (AchR+) who was transferred to our neurological intensive care unit with worsening generalized weakness, dysphagia, and respiratory distress. The crisis was triggered by pneumonia due to dysphagia. He was diagnosed with myasthenic crisis and treated with intravenous pyridostigmine, plasmapheresis (PLEX), and continued prednisone. Initial improvement was followed by deterioration, requiring readmission and additional PLEX. After a further decline, efgartigimod was administered, leading to significant improvement within 48 hours, as evidenced by reduced MG-ADL and QMG scores. The patient continued to improve and was stable enough for transfer to a rehabilitation facility. This case illustrates the potential of efgartigimod as a novel treatment for refractory myasthenic crises.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
将依夫加替莫德作为治疗难治性肌无力危象患者的救治药物
肌无力危象(MC)是一种可能危及生命的重症肌无力症(MG)急性加重期,其特点是肌肉极度无力、出现球部症状并可能导致呼吸衰竭。静脉注射免疫球蛋白(IVIG)和血浆置换(PLEX)是治疗肌无力加重的传统方法。最近,针对全身乙酰胆碱受体抗体阳性(AchR+)的 MG 的新疗法被批准作为附加疗法。它们主要包括补体 C5 抑制剂(如 eculizumab 和 ravulizumab)和新生儿 Fc 受体拮抗剂(如 efgartigimod),还有更多治疗方案(如 zilucoplan 和 rozanolixizumab)有待批准。更多的治疗方案正在审批中。尽管数据显示治疗反应迅速可靠,但这些药物尚未用于肌无力危象的治疗研究。我们报告了一例 57 岁男性患者的病例,他是第一次全身性肌无力(MG)发作,乙酰胆碱受体抗体(AchR+)阳性,因全身乏力、吞咽困难和呼吸窘迫恶化而转入我们的神经重症监护病房。由于吞咽困难,肺炎引发了危机。他被诊断为肌无力危象,接受了静脉注射吡啶斯的明、血浆置换术(PLEX)和持续泼尼松治疗。最初病情有所好转,但随后又出现恶化,需要再次入院并追加 PLEX。病情进一步恶化后,患者接受了依加替莫德治疗,48 小时内病情明显好转,MG-ADL 和 QMG 评分均有所下降。患者病情持续好转,稳定到足以转入康复机构。本病例说明了依加替莫德作为一种新型疗法治疗难治性肌无力危象的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
26
审稿时长
11 weeks
期刊最新文献
Disseminated Intracranial and Spinal Neurenteric Cysts: A Case Report and Literature Review. New-Onset Focal to Bilateral Tonic-Clonic Seizure Following COVID-19 Vaccination. Endotracheal Oxygen Insufflation Associated with Life-Threatening Barotrauma during Apnea Testing. Severe Neurotoxicity due to Atropa belladonna Poisoning: A Case Report and Literature Review. Rhabdomyolysis Induced by Levetiracetam: A Case Report in Kuwait.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1